STREAMING NOW: Watch Now

Scientists make 'exciting' advancement in certain breast cancer drugs

Two new drugs for advanced HER2-positive breast cancer were tested in separate studies, and scientists say they've made progress in the development of new tr...

Posted: Dec 17, 2019 8:29 AM

Two new drugs for advanced HER2-positive breast cancer were tested in separate studies, and scientists say they've made progress in the development of new treatment options.

This type of breast cancer tests positive for higher levels of a protein called HER2.

One study, published in the New England Journal of Medicine last week, found that adding the experimental drug tucatinib to a chemotherapy regimen consisting of the drugs trastuzumab and capecitabine could improve survival for adults with advanced HER2-positive metastatic breast cancer.

The other study, also published in the New England Journal of Medicine last week, found that the experimental drug conjugate called trastuzumab deruxtecan was able to substantially reduce tumor activity in patients with HER2-positive metastatic breast cancer.

"Both studies are evaluating new drugs for HER2-positive breast cancer, which represents about 15% to 20% of all breast cancers," said Dr. Eric Winer, chief of the division of breast oncology at Dana-Farber Cancer Institute in Boston and professor of medicine at Harvard Medical School, who was the senior author of the tucatinib study.

"What's so exciting is we have developed multiple new drugs for HER2-positive breast cancer -- we have new drugs for all subtypes of breast cancer -- but the changes are most dramatic in the setting of HER2-positive breast cancer," Winer said.

"It is the single area in breast cancer where we have made the most dramatic progress and continue to," he said. "For individuals with advanced breast cancer we can individualize therapy more than in the past; it is no longer one size fits all."

The tucatinib study: 'It was pretty well tolerated'

The tucatinib study included 613 patients who previously underwent chemotherapy for HER2-positive metastatic breast cancer by taking the drugs trastuzumab, pertuzumab and trastuzumab emtansine -- but that treatment approach had stopped working for the patients.

For the study, the patients were randomly assigned to either the drug tucatinib or a placebo and received chemotherapy with the drugs trastuzumab and capecitabine.

The researchers found that in the first year of treatment, 33.1% of patients in the tucatinib group did not see their cancer progress compared with 12.3% of patients in the placebo group.

The researchers also found that overall survival two years after starting treatment was 44.9% among patients in the tucatinib group and 26.6% among those in the placebo group.

Side effects of the tucatinib treatment that emerged in the study included the risks of diarrhea and elevated levels of an enzyme in the body called aminotransferase.

"But in general it was pretty well tolerated," Winer said.

Next year, the biotechnology company Seattle Genetics, which develops tucatinib, plans to submit a new drug application to the US Food and Drug Administration and an application to the European Medicines Agency with the goal of bringing this new medicine to the public, Dr. Roger Dansey, chief medical officer at the company, said in a press release on Wednesday.

"Continued innovation to bring new therapies for the treatment of metastatic HER2-positive breast cancer is urgently needed, and we are encouraged by the impressive clinical activity demonstrated with the addition of tucatinib to trastuzumab and capecitabine," he said in part.

The trastuzumab deruxtecan study: 'I am cautiously optimistic'

The trastuzumab deruxtecan study included 184 patients who had already undergone multiple prior treatments for HER2-positive breast cancer. The patients were given the recommended dose of trastuzumab deruxtecan at 5.4 mg per kilogram of body weight.

The researchers found that the patients saw no further progression of their cancer for a median of 16.4 months and that the cancer in 60.9% of the patients shrunk by at least 50% in response to the treatment. However, the treatment came with some side effects, including nausea, myelosuppression -- the decline of bone marrow activity -- and interstitial lung disease.

Overall, "it is rare that a drug has effects on women heavily pretreated," said Dr. Otis Brawley, Bloomberg Distinguished Professor of oncology and epidemiology at Johns Hopkins University, who was not involved in the new study.

"I am cautiously optimistic," he said, but added that more research is needed to determine whether trastuzumab deruxtecan could help patients live longer.

Dr. Ian Krop, a principal investigator of the study and associate chief of the division of breast oncology at Dana-Farber Cancer Institute in Boston, called the research results "striking" in a press release on Wednesday.

"These results are particularly striking as trastuzumab deruxtecan prompted a high level of durable tumor reduction among patients, the majority of whom had exhausted most if not all standard therapies for HER2-metastatic breast cancer," he said. "We are excited by these results and their potential to help patients with this advanced stage of breast cancer."

Mississippi Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 61125

Reported Deaths: 1711
CountyConfirmedDeaths
Hinds5209106
DeSoto328027
Madison228154
Rankin212428
Harrison209832
Jackson192934
Jones176557
Forrest163153
Washington148032
Lauderdale132388
Lee123230
Neshoba119487
Lamar111512
Oktibbeha105235
Lowndes97332
Warren96426
Scott95317
Bolivar93932
Copiah90924
Panola90711
Sunflower90622
Lafayette8699
Holmes84347
Leflore83259
Pike82632
Grenada81220
Yazoo77311
Leake76725
Lincoln74339
Wayne73221
Pontotoc7247
Simpson71126
Monroe69750
Coahoma65910
Tate64523
Marion59918
Adams58025
Covington57811
Winston57115
Marshall5668
George5415
Union51913
Newton51611
Attala49524
Tallahatchie49310
Pearl River48236
Walthall44218
Chickasaw43519
Noxubee41710
Claiborne40013
Smith37713
Jasper3758
Calhoun3748
Clay36814
Alcorn3544
Prentiss3376
Hancock32614
Tishomingo3163
Yalobusha31610
Lawrence3135
Itawamba30710
Tippah30412
Clarke29825
Montgomery2913
Humphreys26911
Tunica2656
Carroll24511
Greene22611
Kemper22315
Perry2217
Quitman2211
Amite2105
Jefferson Davis1986
Webster19712
Jefferson1916
Wilkinson18712
Sharkey1801
Stone1483
Choctaw1264
Benton1240
Franklin1142
Issaquena211
Unassigned00

Alabama Coronavirus Cases

Confirmed Cases: 89927

Reported Deaths: 1580
CountyConfirmedDeaths
Jefferson11650225
Mobile8998191
Montgomery6198143
Madison493225
Tuscaloosa391263
Baldwin317522
Shelby300232
Marshall294730
Unassigned263351
Lee249140
Morgan220615
Etowah191425
DeKalb167713
Elmore158437
Calhoun15359
Walker145763
Houston130912
Dallas128023
Russell12201
Franklin118420
Limestone118313
St. Clair118212
Cullman111311
Colbert107612
Lauderdale105312
Autauga101020
Escambia96515
Talladega89013
Jackson8163
Chambers81438
Tallapoosa80478
Dale77619
Butler75135
Blount7223
Covington70420
Coffee7035
Chilton6976
Pike6547
Barbour5625
Lowndes54624
Marion53524
Marengo51514
Clarke4849
Hale44925
Bullock43711
Perry4284
Winston42811
Wilcox4029
Monroe3884
Randolph38810
Conecuh37110
Bibb3643
Pickens3639
Sumter36118
Washington31011
Macon30813
Lawrence3060
Crenshaw2843
Choctaw27312
Henry2433
Greene24011
Cherokee2337
Geneva2260
Clay2165
Lamar1942
Fayette1695
Cleburne1141
Coosa902
Out of AL00
Tupelo
Overcast
84° wxIcon
Hi: 91° Lo: 70°
Feels Like: 87°
Columbus
Clear
86° wxIcon
Hi: 90° Lo: 68°
Feels Like: 91°
Oxford
Few Clouds
77° wxIcon
Hi: 87° Lo: 65°
Feels Like: 78°
Starkville
Clear
86° wxIcon
Hi: 90° Lo: 66°
Feels Like: 89°
WTVA Radar
WTVA Temperatures
WTVA Severe Weather